Lmcg Investments LLC Sells 2,181 Shares of Inspire Medical Systems, Inc. $INSP

Lmcg Investments LLC lessened its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 7.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,659 shares of the company’s stock after selling 2,181 shares during the quarter. Lmcg Investments LLC owned 0.09% of Inspire Medical Systems worth $3,330,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Inspire Medical Systems by 253.7% in the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company’s stock worth $91,000 after acquiring an additional 411 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Inspire Medical Systems by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 4,055 shares of the company’s stock worth $646,000 after acquiring an additional 521 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Inspire Medical Systems by 19.0% in the 1st quarter. Handelsbanken Fonder AB now owns 10,000 shares of the company’s stock worth $1,593,000 after acquiring an additional 1,600 shares in the last quarter. Fifth Third Bancorp grew its stake in shares of Inspire Medical Systems by 66.2% in the 1st quarter. Fifth Third Bancorp now owns 2,698 shares of the company’s stock worth $430,000 after acquiring an additional 1,075 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV bought a new stake in shares of Inspire Medical Systems in the 1st quarter worth $1,748,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Down 6.1%

Shares of NYSE:INSP opened at $75.23 on Friday. The firm has a market capitalization of $2.22 billion, a PE ratio of 43.49, a P/E/G ratio of 2.50 and a beta of 1.16. Inspire Medical Systems, Inc. has a twelve month low of $70.77 and a twelve month high of $216.01. The company has a 50-day moving average price of $84.07 and a two-hundred day moving average price of $121.81.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 4th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.23. The firm had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the business earned $0.32 earnings per share. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems declared that its Board of Directors has authorized a share repurchase program on Monday, August 11th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to buy up to 8.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on INSP. Truist Financial reiterated a “hold” rating and issued a $125.00 target price (down previously from $190.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 5th. UBS Group set a $89.00 target price on shares of Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Morgan Stanley reduced their target price on shares of Inspire Medical Systems from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Piper Sandler reduced their price target on shares of Inspire Medical Systems from $233.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Finally, Lake Street Capital set a $150.00 price target on shares of Inspire Medical Systems and gave the company a “buy” rating in a research report on Tuesday, August 5th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $150.50.

Insiders Place Their Bets

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the transaction, the chief financial officer owned 44,867 shares in the company, valued at $4,190,129.13. This trade represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.